News

July 19, 2017

Opdivo Extends Survival, Has Less Impact on Lives in Head and Neck Cancer Patients Than Standard Chemo, Study Shows

News

The immunotherapy Opdivo (nivolumab) is less aggressive than standard-of-care chemotherapy for patients with recurrent or metastatic head and neck cancer, and has less of an impact on patients’ quality of ... Read more

July 18, 2017July 18, 2017

Celgene Working with BeiGene to Develop Its PD-1 Inhibitor, BGB-A317, to Treat Solid Tumors

News

Celgene Corporation has entered a strategic collaboration with BeiGene to develop and commercialize its PD-1 inhibitor BGB-A317, an immunotherapy primarily aimed at treating solid tumors, in the U.S., Europe, Japan and much of the world, ... Read more

July 17, 2017

Phase 3 Trial to Assess Cabometyx Combo Therapies vs. Sutent in Advanced Kidney Cancer Patients

News

Exelixis and Bristol-Myers Squibb are starting a Phase 3 trial called CheckMate 9ER to assess Cabometyx (cabozantinib) in combination with immune checkpoint inhibitors in patients with newly-diagnosed advanced renal cell carcinoma, the ... Read more

July 14, 2017

PDS, Merck to Launch Trial Testing Combo Therapy in Treating Certain Head and Neck Cancer Patients

News

PDS Biotechnology Corporation and a subsidiary of Merck are collaborating to develop a Phase 2 clinical trial for a combination cancer treatment for people with certain types of head and neck ... Read more

July 13, 2017

$3.75 Million in Grants to Help ViraCyte Continue Working on Therapies to Combat Post-transplant Viruses

News

ViraCyte has received a combined $3.75 million from the National Institutes of Health and the U.S. Food and Drug Administration to continue developing T-cell immunotherapies for viruses associated with stem ... Read more

July 12, 2017

Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies

News

Researchers at Johns Hopkins University have discovered that variations in gene expression levels can provide insight into mechanisms that allow tumors to respond to immunotherapies. The study, “Transcriptional Mechanisms of ... Read more

July 11, 2017

Mirati Hosts Key Opinion Leader Breakfast on Immuno-oncology Combinations in NYC

News

Mirati Therapeutics hosted a key opinion leader breakfast on immuno-oncology combinations on July 11 in New York City, the company announced in a press release. Featured at the breakfast were presentations by ... Read more

July 10, 2017July 10, 2017

Cancer Research Institute Announces $1 Million Technology Impact Award Winner

News

Dongeun Huh, PhD, from the University of Pennsylvania’s Department of Bioengineering, is the recipient of the Cancer Research Institute’s (CRI) inaugural Technology Impact Award to advance the field of immuno-oncology. Huh will receive a ... Read more

July 7, 2017July 7, 2017

Opdivo Keeps Melanoma from Recurring Longer Than Yervoy, Phase 3 Clinical Trial Shows

News

It took longer for advanced melanoma to recur in patients treated with Bristol-Myers Squibb’s Opdivo (nivolumab) than in patients who received Yervoy, according to a Phase 3 clinical trial. The findings ... Read more

July 6, 2017July 6, 2017

CRI’s 2017 Immunotherapy Patient Series Launches July 8 in San Francisco

News

Registration is now open for the 2017 Immunotherapy Patient Summit Series, a set of free half-day events in five U.S. cities focusing on immunotherapy and clinical trials, says the Cancer Research Institute (CRI). ... Read more